Novacyt Lands New US Supply Deal, Maps Path To Profitability
Executive Summary
Novacyt is continuing its quest to reach profitability in 2018. The French diagnostics group has entered into a partnership with US lab Genesis Diagnostics to develop and supply molecular assay panels for a range of indications. The five-year deal is worth a minimum of $3m, but Novacyt said it expects the agreement to deliver more significant returns.